Answers are grounded in this paper and cite their sources.
Background: Portal cavernoma, a complex vascular disease characterized by the formation of a branch structure because of portal vein thrombosis, remains a significant clinical concern. This study explores the current understanding of the molecular mechanism, including dysregulation of angiogenesis signaling, immunological chain reactions and impaired endothelial function for cavernoma development. Objective: There is no FDA-approved specific drug for portal vein complications. Hence objective of this review is to maximize treatment and enhance patient outcomes, by a collaborative effort, comprising gastrointestinal specialists, interventional radiologists and hepatobiliary surgeons to improve long-term results and quality of life for these patients. Methods: Drug therapies aimed at VEGF, or TGF-β, along with hypoxia-inducible elements, exhibit potential to manage portal cavernoma. Current biological findings have uncovered new pathways driving their origins, resulting in possible drug targets and novel treatment techniques. Growing approaches to treatment, mainly anti-angiogenic medications, focused on genetic therapy and immune system modulation, suggest the potential in addition to conventional blood coagulation, along with surgical techniques. Results: Current treatment strategies frequently rely on case reports that lack defined treatment standards. Long-term outcomes of various therapeutic techniques, optimal anticoagulation strategies and the involvement of endovascular or surgical therapies are all important areas that require additional research. Despite the serious clinical implications, portal cavernoma remains underrepresented in the literature. Conclusion: This review highlighted the requirement for necessary clinical understanding for management and further investigation into this complex disorder and also covers the gaps in understanding molecular mechanisms, utilizing standardized therapeutic strategies and focusing on individualized treatment plans for patients of portal cavernoma.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: